Top Markets
Coin of the day
Sangamo Therapeutics, Inc. Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

GBY
Rankning i aktier #11086
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines designed to significantly improve patients' lives. The company employs cutting-edge platform technologies, including gene therapy, cell therapy, genome editing, and genome regulation. Central to their technological approach is the zinc finger protein (ZFP) platform, which provides both ZFP nucleases for precise DNA sequence modification (allowing for gene addition or knockout) and ZFP transcription factors for upregulating or downregulating gene expression. Their development pipeline includes SB-525, currently in a Phase III AFFINE clinical trial for hemophilia A; ST-920, a gene therapy in Phase I/II STAAR trials for Fabry disease; and SAR445136, a cell therapy undergoing Phase I/II PRECIZN-1 trials for sickle cell disease. Additionally, Sangamo is advancing TX200, a chimeric antigen receptor for HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy targeting cancer; ST-501 for tauopathies; and ST-502 for synucleinopathies, which include Parkinson's disease and other neuromuscular disorders. The company maintains extensive collaborative and strategic partnerships with prominent organizations such as Biogen MA, Inc., Pfizer Inc., Sanofi S.A., Novartis Institutes for BioMedical Research, Inc., and F. Hoffmann-La Roche Ltd. Originally incorporated in 1995 as Sangamo BioSciences, Inc., the company adopted its current name in January 2017 and is headquartered in Brisbane, California.
Aktiekurs
$5.21
Senast synkroniserad: 2022-08-11
Marknadsvärde
$745.49M
Förändring (1 dag)
0.15%
Förändring (1 år)
0.00%
Land
US
Handel Sangamo Therapeutics, Inc. (GBY)

Kategori

EPS för Sangamo Therapeutics, Inc. (GBY)
EPS per 2026 TTM: 0
Enligt Sangamo Therapeutics, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Sangamo Therapeutics, Inc. från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter
Företag EPS EPS-differens Land
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH